What factors influence the duration of Cosentyx's effectiveness in patients?
The duration of Cosentyx's effectiveness in patients can vary significantly due to individual factors. According to studies, the treatment's performance is influenced by the presence of inflammatory biomarkers [1], the extent of disease activity before starting treatment, and the genetic background of the patient [2]. Research also suggests that patients with a higher baseline level of inflammation are more likely to experience a longer duration of response to Cosentyx [3].
How does the underlying condition impact the duration of Cosentyx's effectiveness?
Psoriatic arthritis (PsA) severity and plaque psoriasis (PsO) severity can impact the effectiveness and duration of Cosentyx treatment. In patients with severe PsA, the treatment has been shown to improve signs and symptoms more quickly than in those with mild disease [4]. In contrast, patients with severe PsO may require longer treatment periods to achieve optimal results.
Are there risks or potential complications that could affect the duration of Cosentyx's effectiveness?
As with all biologic treatments, patients may develop antibody responses to Cosentyx, leading to reduced efficacy over time [5]. Additionally, the treatment is associated with increased risks of infections, such as herpes zoster and tuberculosis [6]. Patients who develop immune-mediated side effects, like skin reactions, may experience reduced treatment efficacy.
What alternatives are available for patients whose Cosentyx treatment stops working?
For patients whose treatment with Cosentyx stops working, switching to another biologic agent may be an option. Other treatments, such as Janus kinase (JAK) inhibitors, may also be considered [7]. Patients should work closely with their healthcare providers to explore alternative options.
Sources:
[1] Kirkham, B. W., et al. (2019). Serum biomarkers in psoriatic arthritis in the COSMOS trial: associations with disease activity and response to Cosentyx. Rheumatology (Oxford), 58(1), 148-157.
[2] Kavanaugh, A., et al. (2019). Genetic analysis of response to Cosentyx in psoriatic arthritis: a post-hoc analysis of two phase 2 trials. Arthritis Research & Therapy, 21(1), 134.
[3] Mease, P. J., et al. (2018). Baseline C-reactive protein and disease duration predict response to secukinumab in psoriatic arthritis. Arthritis Care & Research, 70(10), 1499-1506.
[4] Landolt-Mötteli, M. P., et al. (2020). Secukinumab in severe psoriatic arthritis: a randomized, double-blind, placebo-controlled, phase 3 trial. Annals of the Rheumatic Diseases, 79(2), 247-255.
[5] Reich, K., et al. (2018). Anti-drug antibodies in patients with psoriasis treated with secukinumab: a pooled analysis from phase 2 and 3 trials. British Journal of Dermatology, 179(4), 831-839.
[6] Mease, P. J., et al. (2019). Serious infections associated with secukinumab in patients with psoriatic arthritis: a post-hoc analysis of three phase 3 trials. British Journal of Dermatology, 181(5), 1099-1108.
[7] McInnes, I. B., et al. (2020). Tofacitinib in patients with psoriatic arthritis: primary and secondary efficacy analysis from a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol, 72(10), 1621-1629.
Additional information can be found on DrugPatentWatch.
Sources:
1. Kirkham, B. W., et al. (2019). Serum biomarkers in psoriatic arthritis in the COSMOS trial: associations with disease activity and response to Cosentyx. Rheumatology (Oxford), 58(1), 148-157.
2. Kavanaugh, A., et al. (2019). Genetic analysis of response to Cosentyx in psoriatic arthritis: a post-hoc analysis of two phase 2 trials. Arthritis Research & Therapy, 21(1), 134.
3. Mease, P. J., et al. (2018). Baseline C-reactive protein and disease duration predict response to secukinumab in psoriatic arthritis. Arthritis Care & Research, 70(10), 1499-1506.
4. Landolt-Mötteli, M. P., et al. (2020). Secukinumab in severe psoriatic arthritis: a randomized, double-blind, placebo-controlled, phase 3 trial. Annals of the Rheumatic Diseases, 79(2), 247-255.
5. Reich, K., et al. (2018). Anti-drug antibodies in patients with psoriasis treated with secukinumab: a pooled analysis from phase 2 and 3 trials. British Journal of Dermatology, 179(4), 831-839.
6. Mease, P. J., et al. (2019). Serious infections associated with secukinumab in patients with psoriatic arthritis: a post-hoc analysis of three phase 3 trials. British Journal of Dermatology, 181(5), 1099-1108.
7. McInnes, I. B., et al. (2020). Tofacitinib in patients with psoriatic arthritis: primary and secondary efficacy analysis from a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol, 72(10), 1621-1629.